Medicure Inc (MPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medicure Inc (MPH) has a cash flow conversion efficiency ratio of -0.144x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-1.82 Million ≈ $-1.32 Million USD) by net assets (CA$12.65 Million ≈ $9.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Medicure Inc to measure how much of total assets are equity-financed.
Medicure Inc - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Medicure Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Medicure Inc (MPH) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Medicure Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medicure Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Akora Resources Ltd
AU:AKO
|
-0.058x |
|
Hammer Metals Limited
F:6HM
|
-0.006x |
|
Orgenesis Inc
NASDAQ:ORGS
|
0.193x |
|
SKY E&M Co. Ltd
KQ:131100
|
0.027x |
|
Edinburgh Worldwide Investment Trust plc
LSE:EWI
|
-0.013x |
|
Cenntro Electric Group Ltd
NASDAQ:CENN
|
-0.019x |
|
Aakash Exploration Services Limited
NSE:AAKASH
|
0.010x |
|
Jupiter Fund Management Plc
LSE:JUP
|
0.024x |
Annual Cash Flow Conversion Efficiency for Medicure Inc (2000–2025)
The table below shows the annual cash flow conversion efficiency of Medicure Inc from 2000 to 2025. For the full company profile with market capitalisation and key ratios, see Medicure Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$12.91 Million ≈ $9.34 Million |
CA$-560.00K ≈ $-405.10K |
-0.043x | -165.46% |
| 2024-12-31 | CA$20.78 Million ≈ $15.03 Million |
CA$1.38 Million ≈ $996.10K |
0.066x | -36.58% |
| 2023-12-31 | CA$19.90 Million ≈ $14.39 Million |
CA$2.08 Million ≈ $1.50 Million |
0.104x | +20.07% |
| 2022-12-31 | CA$21.00 Million ≈ $15.19 Million |
CA$1.83 Million ≈ $1.32 Million |
0.087x | -59.83% |
| 2021-12-31 | CA$18.41 Million ≈ $13.32 Million |
CA$3.99 Million ≈ $2.89 Million |
0.217x | +285.19% |
| 2020-12-31 | CA$19.15 Million ≈ $13.85 Million |
CA$-2.24 Million ≈ $-1.62 Million |
-0.117x | +78.47% |
| 2019-12-31 | CA$26.94 Million ≈ $19.49 Million |
CA$-14.64 Million ≈ $-10.59 Million |
-0.543x | -6219.98% |
| 2018-12-31 | CA$83.59 Million ≈ $60.47 Million |
CA$742.27K ≈ $536.95K |
0.009x | -96.73% |
| 2017-12-31 | CA$80.71 Million ≈ $58.38 Million |
CA$21.92 Million ≈ $15.86 Million |
0.272x | +65.07% |
| 2016-12-31 | CA$38.96 Million ≈ $28.18 Million |
CA$6.41 Million ≈ $4.64 Million |
0.165x | +414.14% |
| 2015-12-31 | CA$4.46 Million ≈ $3.23 Million |
CA$142.79K ≈ $103.30K |
0.032x | +126.41% |
| 2014-12-31 | CA$-3.91 Million ≈ $-2.83 Million |
CA$473.97K ≈ $342.86K |
-0.121x | -542.33% |
| 2013-12-31 | CA$-5.88 Million ≈ $-4.25 Million |
CA$110.88K ≈ $80.21K |
-0.019x | -108.24% |
| 2012-12-31 | CA$-4.33 Million ≈ $-3.13 Million |
CA$-990.48K ≈ $-716.50K |
0.229x | +199.88% |
| 2011-12-31 | CA$-1.82 Million ≈ $-1.32 Million |
CA$417.29K ≈ $301.86K |
-0.229x | -1190.93% |
| 2010-12-31 | CA$-26.89 Million ≈ $-19.45 Million |
CA$477.48K ≈ $345.40K |
-0.018x | -130.50% |
| 2009-12-31 | CA$-24.96 Million ≈ $-18.05 Million |
CA$-1.45 Million ≈ $-1.05 Million |
0.058x | -89.08% |
| 2008-12-31 | CA$-19.55 Million ≈ $-14.14 Million |
CA$-10.42 Million ≈ $-7.54 Million |
0.533x | -91.65% |
| 2007-12-31 | CA$-6.56 Million ≈ $-4.74 Million |
CA$-41.86 Million ≈ $-30.28 Million |
6.386x | +967.70% |
| 2006-12-31 | CA$34.31 Million ≈ $24.82 Million |
CA$-25.25 Million ≈ $-18.26 Million |
-0.736x | -115.75% |
| 2005-12-31 | CA$37.17 Million ≈ $26.89 Million |
CA$-12.68 Million ≈ $-9.17 Million |
-0.341x | +79.25% |
| 2004-12-31 | CA$7.34 Million ≈ $5.31 Million |
CA$-12.07 Million ≈ $-8.73 Million |
-1.644x | -476.36% |
| 2003-12-31 | CA$21.57 Million ≈ $15.60 Million |
CA$-6.15 Million ≈ $-4.45 Million |
-0.285x | +64.61% |
| 2002-12-31 | CA$4.94 Million ≈ $3.58 Million |
CA$-3.98 Million ≈ $-2.88 Million |
-0.806x | -73.80% |
| 2001-12-31 | CA$8.99 Million ≈ $6.50 Million |
CA$-4.17 Million ≈ $-3.01 Million |
-0.464x | +34.57% |
| 2000-12-31 | CA$3.85 Million ≈ $2.79 Million |
CA$-2.73 Million ≈ $-1.97 Million |
-0.709x | -- |
About Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary … Read more